Data / Form D filings / CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc.: Form D filings
CASI Pharmaceuticals, Inc., a pharmaceuticals company in Beijing, China, filed 5 Form D notices with the SEC between 2024 and 2026. The latest, on April 28, 2026, reports $5 million sold of a $5 million offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1701-1702, CHINA CENTRAL OFFICE TOWER 1 NO. 81 JIANGUO ROAD, CHAOYANG DISTRICT, Beijing, China, 10002
- Phone
- 86 10 6561 8789
- Industry
- Pharmaceuticals
- Entity type
- Other
- Incorporated in
- Cayman Islands
- Year incorporated
- 2023
- Revenue range
- $5,000,001 - $25,000,000
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1962738
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | New notice | $5,000,000 | $5,000,000 | 1 | Apr 17, 2026 | sec.gov | |
| Feb 26, 2026 | New notice | $5,000,000 | $5,000,000 | 1 | Feb 19, 2026 | sec.gov | |
| Jan 28, 2026 | New notice | $5,000,000 | $5,000,000 | 1 | Jan 9, 2026 | sec.gov | |
| Jan 28, 2026 | New notice | $5,000,000 | $5,000,000 | 1 | Dec 27, 2025 | sec.gov | |
| Jul 15, 2024 | New notice | $15,000,000 | $15,000,000 | 7 | Jun 26, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Wei-Wu He | Director | Chairman to the Board |
| Zhenbo Su | Director | |
| Thomas Folinsbee | Director | |
| Alexander Y. Wu | Director | |
| Xuebo Zeng | Director | |
| Wei Gao | Executive Officer | General Counsel |
| Kun Qian | Executive Officer | Global Controller |
| Chunhua Wang | Executive Officer | Chief Operating Officer |
| Hai Huang | Executive Officer | Global Chief Commercial Officer |
| Wei (Larry) Zhang | Executive Officer | Vice President |
| James Huang | Director | |
| Barbara Krebs-Pohl | Director |
Every Form D from the week of Apr 27, 2026 · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what CASI Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.